Literature DB >> 7706474

Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

E H Chen1, E E Johnson, S M Vetter, B S Mitchell.   

Abstract

Deoxycytidine kinase (dCK) phosphorylates 2'-deoxycytidine, as well as the purine deoxyribonucleosides and a number of nucleoside analogues that are important in the chemotherapy of leukemias. The enzyme is highly expressed in the thymus relative to other tissues and may play an important role in the T cell depletion associated with adenosine deaminase and purine nucleoside phosphorylase deficiencies. To characterize the dCK promoter region and to determine whether it mediates higher levels of gene expression in T lymphoblasts, we have analyzed a 700-bp genomic fragment encompassing 548 bp of 5' flanking region for functional activity and for transcription factor binding using T and B lymphoblast cell lines and nuclear extracts. The regions of the promoter that were defined as important to its function include a 5' GC box, and E box, a 3' GC box, and an E2F site. The transcription factor Sp1 binds to both GC boxes, activating at the 5' site but repressing at the 3' site. MLTF/USF activates transcription through the E box, whereas E2F activates through the E2F site, but binds weakly to this site in vitro and does not appear to mediate cell cycle-specific expression of dCK in vivo. No significant differences in promoter activity or transcription factor binding were observed between Jurkat T and Raji B lymphoblasts. The promoter of the dCK gene is thus regulated by a number of ubiquitously expressed transcription factors. DCK expression in cultured lymphoblast cell lines is not solely a function of the T or B lineage derivation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706474      PMCID: PMC295671          DOI: 10.1172/JCI117841

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues.

Authors:  E S Arnér; T Spasokoukotskaja; S Eriksson
Journal:  Biochem Biophys Res Commun       Date:  1992-10-30       Impact factor: 3.575

2.  E2F: a link between the Rb tumor suppressor protein and viral oncoproteins.

Authors:  J R Nevins
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

3.  Interaction of Sp1 with the human gamma globin promoter: binding and transactivation of normal and mutant promoters.

Authors:  D L Gumucio; K L Rood; K L Blanchard-McQuate; T A Gray; A Saulino; F S Collins
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

4.  Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.

Authors:  J K Owens; D S Shewach; B Ullman; B S Mitchell
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

5.  Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene.

Authors:  A Riccio; P V Pedone; L R Lund; T Olesen; H S Olsen; P A Andreasen
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

6.  The HIP1 binding site is required for growth regulation of the dihydrofolate reductase gene promoter.

Authors:  A L Means; J E Slansky; S L McMahon; M W Knuth; P J Farnham
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

7.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

8.  A sensitive method for the detection of beta-galactosidase in transfected mammalian cells.

Authors:  D C Eustice; P A Feldman; A M Colberg-Poley; R M Buckery; R H Neubauer
Journal:  Biotechniques       Date:  1991-12       Impact factor: 1.993

9.  E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection.

Authors:  M Wade; T F Kowalik; M Mudryj; E S Huang; J C Azizkhan
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

10.  Cell cycle regulation of the human cdc2 gene.

Authors:  S Dalton
Journal:  EMBO J       Date:  1992-05       Impact factor: 11.598

View more
  8 in total

Review 1.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

2.  Changes in 2'-deoxycytidine levels in various tissues of tumor-bearing mice.

Authors:  Ayano Iwazaki; Kimie Imai; Kunio Nakanishi; Masanori Yoshioka
Journal:  Oncol Lett       Date:  2010-09-08       Impact factor: 2.967

3.  Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.

Authors:  I Hubeek; G J Peters; A J F Broekhuizen; I Talianidis; J Sigmond; B E S Gibson; U Creutzig; G Giaccone; G J L Kaspers
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

4.  Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells.

Authors:  Annamaria Innoceta; Luca Galluzzi; Annamaria Ruzzo; Francesca Andreoni; Laura Chiarantini; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2002-02       Impact factor: 3.396

5.  DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

Authors:  Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

6.  Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.

Authors:  M Maftouh; A Avan; R Sciarrillo; C Granchi; L G Leon; R Rani; N Funel; K Smid; R Honeywell; U Boggi; F Minutolo; G J Peters; E Giovannetti
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

7.  siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.

Authors:  Christine Di Cresce; Rene Figueredo; Mateusz Rytelewski; Saman Maleki Vareki; Colin Way; Peter J Ferguson; Mark D Vincent; James Koropatnick
Journal:  Oncotarget       Date:  2015-09-08

8.  Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

Authors:  Meixian Huang; Takeshi Inukai; Kunio Miyake; Yoichi Tanaka; Keiko Kagami; Masako Abe; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Eiji Sugihara; Atsushi Watanabe; Shinpei Somazu; Tamao Shinohara; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.